Nanobiotix announces Curadigm Nanoprimer Platform advancements with updated plans for internal pipeline development and external collaborations (20.27 -1.31)
- Four new patent applications filed that aim to expand the Curadigm Nanoprimer platform intellectual property portfolio and support an initial proprietary internal pipeline of Nanoprimer products in addition to external collaborations.
- New in vivo pre-clinical data evaluating the Nanoprimer in combination with therapeutic vaccines were presented at the 2025 Partnership Opportunities in Drug Delivery conference that will serve as the foundation for an initial internal proprietary pipeline of Nanoprimer products.
- Momentum building for external collaborations featuring Nanoprimer platform combinations with numerous material transfer agreements already in place Chemistry, Manufacturing, and Controls activities launched to support both internal pipeline and external collaborations.